Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Double-Blind Evaluation of Tenofovir Alafenamide in Adolescents with Chronic Hepatitis B Virus Infection
2016-000785-37Phase 2
- Sponsor
- Gilead Sciences
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing TAF 25 mg once daily with Placebo once daily (2 arms). Primary endpoints: Primary safety endpoints, Pharmacokinetics endpoints and 1 more.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2016-000785-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000785-37.